What is the appropriate intravenous polymyxin B dosing regimen for a patient with severe chronic kidney disease (eGFR approximately 12 mL/min/1.73 m²)?

Polymyxin B Dosing in Severe Renal Impairment

For a patient with severe chronic kidney disease (eGFR ~12 mL/min/1.73 m²), start with a loading dose of 150 mg (approximately 2 mg/kg) followed by a reduced maintenance dose of 50 mg every 12 hours (100 mg/day total), with mandatory therapeutic drug monitoring (TDM) to optimize dosing and minimize nephrotoxicity.

Dosing Algorithm for Severe Renal Impairment

Loading Dose

• Administer 150 mg IV regardless of renal function 12
• This loading dose is critical to rapidly achieve therapeutic concentrations
• Infuse over 1 hour

Maintenance Dosing Based on Renal Function

For your patient with eGFR ~12 mL/min/1.73 m²:

• Start with 50 mg IV every 12 hours (100 mg/day total) 3
• The FDA label recommends reducing from the standard 15,000-25,000 units/kg/day (approximately 1-1.67 mg/kg q12h) downward for renal impairment 4
• Recent pharmacokinetic studies confirm that creatinine clearance significantly affects polymyxin B clearance, with typical clearance of 1.59-1.75 L/h in patients with normal function, but substantially reduced in severe renal impairment 562

Critical Monitoring Requirements

Implement TDM immediately - this is strongly recommended by 2023 guidelines for polymyxin therapy 777:

• Target plasma steady-state AUC₂₄h/MIC ratio of ≥50-100 for efficacy
• Monitor trough concentrations (Css,avg target ≥1 mg/L but <5 mg/L to balance efficacy and toxicity)
• A plasma AUCss,24h/MIC threshold of 80.6 has been associated with better clinical outcomes 8
• Adjust doses based on TDM results rather than renal function alone

Dose Adjustments Based on MIC

The pathogen's MIC critically influences dosing:

• MIC ≤0.5 mg/L: 50 mg q12h is sufficient 8
• MIC = 1 mg/L: May require 75-100 mg q12h 62
• MIC ≥2 mg/L: Consider combination therapy or adjunctive nebulized polymyxin, as IV monotherapy may be inadequate even at higher doses 8

Key Clinical Considerations

Renal Replacement Therapy (RRT)

If your patient requires RRT initiation (likely given eGFR of 12):

• Convective modalities (CVVH, CVVHDF): Increase polymyxin B clearance significantly - may require higher maintenance doses (75-100 mg q12h) 1
• Diffusive modalities (CVVHD): Variable effects on clearance - use cautious dosing with TDM guidance 1
• Do not routinely reduce doses during RRT without TDM, as clearance may actually increase

Nephrotoxicity Risk Management

Critical warning: Polymyxin B carries substantial nephrotoxicity risk, especially in patients with pre-existing renal impairment 3:

• Monitor serum creatinine and urine output daily
• In the retrospective case series of patients with renal impairment receiving 100 mg/day, 4 of 5 patients experienced worsening renal function requiring continuous RRT 3
• However, 4 of 5 patients recovered normal renal function after polymyxin discontinuation 3
• Consider combination therapy to potentially reduce polymyxin exposure while maintaining efficacy

Neurotoxicity Monitoring

Watch for:

• Decreased limb muscle strength
• Cognitive impairment
• Paresthesias
• These occurred in 1 of 5 patients with renal impairment in one series 3

Combination Therapy Considerations

Strongly consider combination therapy rather than monotherapy 9:

• Meta-analysis shows colistin-based combination therapy reduced 28-30 day mortality (35.7% vs 55.5%, OR 0.46) compared to monotherapy 9
• Common combination partners include carbapenems (even if resistant, for synergy), tigecycline, or aminoglycosides
• Combination therapy may allow lower polymyxin doses, reducing toxicity risk

Practical Implementation

1. Day 1: Give 150 mg loading dose IV over 1 hour
2. Day 1 (12 hours later): Start 50 mg q12h maintenance dosing
3. Day 2-3: Obtain steady-state trough and peak concentrations for TDM
4. Ongoing: Adjust based on TDM results, clinical response, and renal function trajectory
5. Daily: Monitor renal function, neurological status, and clinical infection parameters

Evidence Quality Note

The FDA label provides standard dosing but lacks specific guidance for severe renal impairment 4. The 2023 guidelines strongly recommend TDM for polymyxins to optimize dosing and reduce toxicity 777. Recent pharmacokinetic studies consistently demonstrate that renal function (measured by CrCL or eGFR) is the most significant covariate affecting polymyxin B clearance 1562, supporting dose reduction in severe renal impairment. However, the relationship is complex and non-linear, making TDM essential rather than relying solely on renal function-based dosing algorithms 10.

The conservative 50 mg q12h starting dose in severe renal impairment balances the need for efficacy against the high risk of further nephrotoxicity in this vulnerable population, with TDM-guided escalation as needed.